scholarly journals Prognostic Significance of Preoperative Serum Triglycerides and High-Density Lipoproteins Cholesterol for Patients with Non-Small Cell Lung Cancer: A Retrospective Study

2021 ◽  
Author(s):  
Cong Ma ◽  
Xiaoyan Wang ◽  
Jingjing Guo ◽  
Ping Liu
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Roc Curve ◽  
Serum Lipids ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Preoperative Serum ◽  
Lipids And Lipoproteins ◽  
Nsclc Patients

Abstract Background: Abnormalities in serum lipids and lipoproteins have been documented to be associated with the risk of various cancers in recent years, but its prognostic value for cancer is not known. This study retrospectively evaluated the prognostic significance of preoperative serum lipids and lipoproteins for non-small cell lung cancer (NSCLC).Methods: A retrospective review was conducted of 551 patients with NSCLC. A receiver operative characteristic (ROC) curve was utilized to determine the optimal cut-off value and area under the ROC curve. Kaplan-Meier curves and a Cox proportional hazards model were used to perform survival analysis.Results: Serum lipids and lipoproteins had significant difference between NSCLC patients and healthy controls. Moreover, with a median follow-up of 42 months, the NSCLC patients in high triglycerides (TG) group and low High-density lipoprotein cholesterol (HDL-C) group exhibited shorter overall survival (OS) and disease-free survival (DFS). In multivariable analysis, preoperative TG and HDL-C can be identified as independent prognostic factors for OS and DFS in patients with NSCLC. Conclusion: Abnormalities of serum lipids and lipoproteins metabolism were associated with the survival outcomes of NSCLC. Preoperative serum TG and HDL-C may be promising biomarkers to predict prognosis for NSCLC patients.

A Meta Analysis on Prognostic Value of Patients with Non-Small Cell Lung Cancer

2018 ◽  
Vol 8 (9) ◽  
pp. 1875-1880
Author(s):  
Jiang Rui ◽  
Li Yingping ◽  
Lijun Gu ◽  
Zhiyan Wang ◽  
Jing Zuo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Small Cell ◽  
Significant Heterogeneity ◽  
Small Cell Lung ◽  
Survival Prognosis ◽  
Nsclc Patients

Nuclear factor kappa B (NF-κB), a key nuclear transcription factor, is associated with prognosis in a variety of human cancers. However, the clinical value of NF-κB in non-small cell lung cancer (NSCLC) is still controversial. Therefore, the aim of this meta-analysis was to obtain an accurate evaluation of the relationship between NF-κB expression and survival prognosis of NSCLC patients based on published articles. PubMed, EMBASE and Web of Science databases were systematically searched for potential articles. A total of 1159 patients from 7 eligible studies comparing prognostic significance of NF-κB expression levels in NSCLC were included in our meta-analysis. I2 statistic and P value were performed to evaluate heterogeneity using Review Manager version 5.3. The results of analysis were presented as hazard ratio (HR) or odds ratios with 95% confidence interval (95% CI). Subgroup analysis based on ethnicity of NSCLC patients was conducted to illustrate the potential discrepancy. Significant heterogeneity was considered at I2 > 50% and P < 0.05, and random-effects model was used. The combined results indicated that higher NF-κB expression was associated with shorter overall survival of NSCLC patients (HR = 2.78, 95% CI = 1.51–5.12, P = 0.001). Moreover, NF-κB expression was closely associated with tumor stage (HR = 0.32, 95% CI = 0.18–0.57, P < 0.0001) and lymph node metastasis (HR = 0.56, 95% CI = 0.38–0.83, P = 0.004). We conclude that NF-κB expression may be a potential unfavorable prognostic marker for NSCLC patients.

Prognostic significance of aneuploidy in non-small cell lung cancer (NSCLC) patients (pts)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7319-7319
Author(s):  
R. Dziadziuszko ◽  
E. Wegrzynowicz ◽  
I. Kardas ◽  
J. Limon ◽  
J. Jassem
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

Retinoblastoma mutation to predict poor outcomes in non-small cell lung cancer (NSCLC).

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 9060-9060
Author(s):  
Priyanka Bhateja ◽  
Gary Wildey ◽  
Pingfu Fu ◽  
Mary Beth Lipka ◽  
Fatemeh Ardeshir-Larijani ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Smoking History ◽  
Secondary Outcome ◽  
P Value ◽  
Small Cell Lung ◽  
Nsclc Patients

9060 Background: Genomic profiling of tumor DNA has revealed the diversity in NSCLC. The retinoblastoma gene ( RB1) encodes for RB pocket protein that plays an important role in cell cycle progression by interacting with various transcriptional factors. Here we determine the frequency and prognostic significance of RB1mutation in NSCLC and compare it to that in small cell lung cancer (SCLC). Methods: This IRB-approved retrospective review on NSCLC patients included Stage III and IV patients with genomic and clinical data. Primary outcome was median overall survival (OS) and secondary outcome was progression-free survival (PFS). OS and PFS were calculated by the Kaplan-Meier method and compared between mutant and wild-type (wt) RB1using the Log-Rank test. The effect of RB1mutation status on OS and PFS was further evaluated using the multivariable Cox model, controlling the effects of age, sex, stage, smoking history and chemotherapy. All tests are two-sided and p-values ≤ 0.05 were considered statistically significant. Results: We identified RB1 mutation in 8.2% of NSCLC patients (16 of 195 patients). With a median follow-up of 15.1 months, the median OS for wt RB1was 28.3 months and for mutant RB1 was 8.3 months (HR = 2.59, p-value = 0.002). The median PFS for wt RB1 was 21.8 months vs 6.4 months for mutant RB1 (HR = 2.85, p-value = 0.0002). RB1 mutation was associated with worse OS ( p= 0.017, HR = 2.17) and PFS ( p= 0.005, HR = 2.37) in multivariate analyses after adjusting for traditional risk factors like, age, sex, stage, smoking history and chemotherapy. Interestingly, a previously described benign deletion (A16-A18) in RB1 protein was identified in 5 of the 16 RB1 mutant patients and was associated with far worse outcomes compared to other RB1 mutations. In contrast to NSCLC, RB1 mutation was identified in 75% of 64 SCLC patients. Furthermore, wt RB1 was associated with significantly shorter OS ( p= 0.002), PFS ( p= 0.004) and chemotherapy refractoriness ( p= 0.033) in SCLC. Conclusions: RB1 mutation is present in a minority of patients with advanced NSCLC and is associated with poor prognosis. In contrast, RB1 mutation is present in the majority of SCLC patients and is associated with a favorable prognosis.

Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer

2016 ◽  
Vol 64 (11) ◽  
pp. 657-661 ◽  
Author(s):  
Masaki Tomita ◽  
Takanori Ayabe ◽  
Eiichi Chosa ◽  
Naohiro Nose ◽  
Kunihide Nakamura
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Preoperative Serum

scholarly journals Circulating CD15+LOX-1+ PMN-MDSCs are a potential biomarker for the early diagnosis of non-small cell lung cancer

2020 ◽  
Author(s):  
Xinyu Tian ◽  
Ting Wang ◽  
Qisi Zheng ◽  
Yue Tao ◽  
Lei Dai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Roc Curve ◽  
Small Cell ◽  
Cytokeratin 19 ◽  
Small Cell Lung ◽  
Potential Biomarker ◽  
Nsclc Patients

Aims: Non-small-cell lung cancer (NSCLC) is the most common clinical lung cancer. Polymorphonuclear-myeloid derived suppressor cells (PMN-MDSCs), which are the major population of MDSCs, are involved in NSCLC progression. Recently, it was found that lectin-type oxidized LDL receptor 1 (LOX-1) could identify humsn PMN-MDSCs. However, the role of CD15+LOX-1+ PMN-MDSCs in NSCLC early diagnosis has not been revealed. Here, we tried to confirm the application of the newly-identified CD15+LOX-1+ PMN-MDSCs in the early diagnosis of NSCLC. Methods: Flow cytometry (FCM) was used to detect the proportion of CD15+LOX-1+ PMN-MDSCs in the peripheral blood (PB) of healthy controls (HC) and NSCLC patients. The correlation of CD15+LOX-1+ PMN-MDSC frequency with levels of cytokeratin 19-fragments (CYFRA21-1), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125) was analyzed. Receiver operating characteristic (ROC) curve was used to estimate the diagnostic efficacy of CD15+LOX-1+ PMN-MDSCs for NSCLC. Additionally, the association of CD15+LOX-1+ PMN-MDSC frequency with NSCLC prognosis/recurrence after surgery was explored. Results: The proportion of CD15+LOX-1+ PMN-MDSCs increased in PB of NSCLC patients. CD15+LOX-1+ PMN-MDSC proportion was positively correlated with levels of CEA and CYFRA21-1. The area under the ROC curve (AUC) of PMN-MDSC percentage was higher than CYFRA21-1, CEA and CA125. The proportion of CD15+LOX-1+ PMN-MDSCs decreased in patients after surgery. The frequency of CD15+LOX-1+ PMN-MDSCs was lower in NSCLC patients without recurrence compared to those with recurrence after surgery. Conclusions: Circulating CD15+LOX-1+ PMN-MDSCs are a potential diagnostic marker for NSCLC, and are associated with NSCLC prognosis and recurrence after surgery.

Prognostic significance of aneuploidy in non-small cell lung cancer (NSCLC) patients (pts)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7319-7319 ◽  
Author(s):  
R. Dziadziuszko ◽  
E. Wegrzynowicz ◽  
I. Kardas ◽  
J. Limon ◽  
J. Jassem
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Prognostic Significance ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

scholarly journals Expression of long noncoding RNA NBAT1 is associated with the outcome of patients with non-small cell lung cancer

2020 ◽  
Vol 66 (7) ◽  
pp. 898-903
Author(s):  
Da-Ling Wang ◽  
Peng Yuan ◽  
Ji-Yuan Tian
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Long Noncoding Rna ◽  
Noncoding Rna ◽  
Prognostic Significance ◽  
Small Cell ◽  
Normal Lung ◽  
Small Cell Lung ◽  
Nsclc Patients

SUMMARY OBJECTIVE Long noncoding RNA neuroblastoma-associated transcript 1 (NBAT1) has been reported to be involved in cancer progression. However, the clinical significance of NBAT1 in non-small cell lung cancer (NSCLC) is still unclear. Our present research aimed to explore whether NBAT1 serves as a biomarker for NSCLC prognosis. METHODS The expression of NBAT1 was examined by RT-PCR in tissue samples of 162 NSCLC patients and was compared with the adjacent non-tumor lung specimens. Then the association between NBAT1 expression and clinical-pathological parameters was further evaluated. Survival analysis was performed using the Kaplan-Meier method. The prognostic significance of NBAT1 expression in NSCLC patients was explored by the use of univariate and multivariate analyses. RESULTS NBAT1 expression was prominently decreased in NSCLC tissues compared with matched normal lung specimens (p < 0.01). Moreover, survival analyses indicated that patients with low expression displayed dramatically decreased 5-year overall survival (p = 0.008). CONCLUSIONS NBAT1 expression might contribute to tumor progression and poor prognosis of NSCLC and might be a new therapeutic target in NSCLC.

scholarly journals Clinical implications for pro-GRP in small cell lung cancer. A single center experience

2017 ◽  
Vol 33 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Stefano Cavalieri ◽  
Daniele Morelli ◽  
Antonia Martinetti ◽  
Giulia Galli ◽  
Federico Nichetti ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Roc Curve ◽  
Prognostic Significance ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Curve Analysis ◽  
Small Cell Lung ◽  
Roc Curve Analysis

Background: Recently, pro-gastrin-releasing peptide (pro-GRP) became available as an alternative sensitive, specific and reliable tumor marker for patients with small cell lung cancer (SCLC), both in limited (LD) and diffuse disease (DD). Methods: We retrospectively analyzed pro-GRP, neuron-specific enolase (NSE) and CEA in patients with SCLC and non-small cell lung cancer (NSCLC). Serum pro-GRP level was measured with electrochemiluminescence at our laboratory (cutoff 77.8 pg/mL). Continuous variables were analyzed with the Mann-Whitney test, contingency data with Fisher’s exact test. Receiver operator characteristic (ROC) curve analysis was performed to identify threshold values to set the highest sensitivity (Sn) and specificity (Sp) values. Results: A total of 65 patients were studied (49 men, median age 67 years, range 27-79). Thirty-seven patients had SCLC (29 DD, 8 LD) and 28 advanced NSCLC. Median pro-GRP level was 919 pg/mL (range 22-147,350) in SCLC and 32 pg/mL (range 10-119.2) in NSCLC (p<0.0001). NSE was 4.38-fold higher in SCLC patients (p = 0.0005); CEA did not reveal significant differences between groups. Pro-GRP Sn and Sp were 86.4% and 96.4%, respectively. With ROC curve analysis, a cutoff value of 329.3 pg/mL showed a Sn of 75.8% and Sp of 87.5% in discriminating DD from LD. Pro-GRP was not influenced by either liver metastases or renal impairment. Conclusions: Pro-GRP is sensitive for SCLC diagnosis. Since high marker levels are related to high disease burden, pro-GRP may have a negative prognostic significance. Follow-up studies are required to define its role in clinical practice in monitoring responses to treatment and early relapses.

scholarly journals Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Cong Ma ◽  
Xiaoyan Wang ◽  
Jingjing Guo ◽  
Ping Liu
Keyword(s):  
Roc Curve ◽  
Serum Lipids ◽  
Proportional Hazards Model ◽  
Prognostic Significance ◽  
Multivariable Analysis ◽  
Cox Proportional Hazards Model ◽  
High Density Lipoproteins ◽  
Preoperative Serum ◽  
Lipids And Lipoproteins ◽  
Nsclc Patients

Abstract Background Abnormalities in serum lipids and lipoproteins have been documented to link to the risk of cancers in recent years, but its prognostic value for cancer is not known. This study retrospectively evaluated the significance of preoperative serum lipids and lipoproteins for NSCLC’s prognosis. Methods A retrospective review was implemented of 551 patients succumbed to NSCLC. A ROC curve was utilized to determine the best cut-off value and area under the ROC curve. Kaplan-Meier and a Cox proportional hazards model were utilized to perform survival analysis. Results With a median follow-up of 42 months, the NSCLC patients in the high TG (> 1.21 mmol/L) and low HDL-C (≤ 1.26 mmol/L) two groups exhibited shorter OS and DFS. In multivariable analysis, preoperative HDL-C and TG can work as independent prognosis factors for OS (P<0.001 for both) and DFS (P<0.05 for both) in patients succumbed to NSCLC. Conclusion Abnormalities of serum lipids and lipoproteins metabolism linked to the survival outcomes of NSCLC. Preoperative serum HDL-C and TG may be promising biomarkers to predict the NSCLC patients’ prognosis.

Sign in / Sign up

Export Citation Format

Share Document